Bioventus Inc. (BVS) - What Are Analysts Thinking About This Stock?

Bioventus logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analyst sentiment is moderately positive: Five of six covering firms rate Bioventus a buy, while one recommends holding; the average 12-month price target is $16.60.
  • Recent views were mixed: Canaccord cut its target from $19 to $18 but maintained a buy rating, while Weiss downgraded the stock to hold. Shares opened at $10.46, below the average target.
  • Bioventus reported quarterly EPS of $0.17, matching estimates, on revenue of $142.44 million. Institutional investors own 62.94% of the shares, with some large investors increasing their holdings.
  • Five stocks to consider instead of Bioventus.

Bioventus Inc. (NASDAQ:BVS - Get Free Report) has been given an average rating of "Moderate Buy" by the six ratings firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $16.60.

BVS has been the subject of several analyst reports. Cantor Fitzgerald reissued an "overweight" rating and issued a $15.00 target price on shares of Bioventus in a report on Monday, August 17th. Canaccord Genuity Group lowered their price target on shares of Bioventus from $19.00 to $18.00 and set a "buy" rating on the stock in a report on Tuesday, November 3rd. Barrington Research set a $18.00 price target on shares of Bioventus in a report on Thursday, August 6th. Wall Street Zen lowered shares of Bioventus from a "strong-buy" rating to a "buy" rating in a research report on Saturday, November 7th. Finally, Weiss Ratings cut shares of Bioventus from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Wednesday, November 4th.

View Our Latest Report on Bioventus

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Goldman Sachs Group Inc. grew its holdings in shares of Bioventus by 28.0% in the third quarter. Goldman Sachs Group Inc. now owns 835,154 shares of the company's stock valued at $11,383,000 after purchasing an additional 182,787 shares in the last quarter. EP Wealth Advisors LLC bought a new stake in Bioventus in the third quarter worth $243,000. Pathstone Holdings LLC purchased a new stake in Bioventus during the third quarter valued at $199,000. Marshall Wace LLP purchased a new stake in Bioventus during the third quarter valued at $1,403,000. Finally, Nantahala Capital Management LLC raised its stake in Bioventus by 7.0% during the third quarter. Nantahala Capital Management LLC now owns 6,420,884 shares of the company's stock valued at $87,517,000 after purchasing an additional 420,605 shares in the last quarter. Institutional investors own 62.94% of the company's stock.

Bioventus Trading Down 1.9%

NASDAQ BVS opened at $10.46 on Tuesday. Bioventus has a 12 month low of $6.47 and a 12 month high of $15.89. The stock has a market cap of $881.37 million, a P/E ratio of 13.08, a P/E/G ratio of 1.39 and a beta of 0.66. The stock's fifty day moving average price is $13.06 and its 200-day moving average price is $11.05. The company has a current ratio of 1.68, a quick ratio of 1.16 and a debt-to-equity ratio of 0.72.

Bioventus (NASDAQ:BVS - Get Free Report) last released its quarterly earnings data on Monday, November 2nd. The company reported $0.17 earnings per share for the quarter, meeting the consensus estimate of $0.17. Bioventus had a net margin of 9.78% and a return on equity of 26.31%. The firm had revenue of $142.44 million during the quarter. As a group, equities analysts forecast that Bioventus will post 0.78 EPS for the current fiscal year.

Bioventus Company Profile

(Get Free Report)

Bioventus Inc. is a medical technology company focused on helping patients recover from musculoskeletal conditions and injuries. Its products and services support bone healing, pain management and surgical care. The company's offerings include noninvasive devices that use ultrasound to support bone healing, injectable treatments for osteoarthritis pain, and surgical products such as bone graft materials and ultrasonic instruments used in procedures. Bioventus began operations in 2012, originating from businesses previously owned by Smith & Nephew.

Further Reading

Analyst Recommendations for Bioventus (NASDAQ:BVS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Bioventus Right Now?

Before you consider Bioventus, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bioventus wasn't on the list.

While Bioventus currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines